Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma.

Trial Profile

Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Multiple myeloma; Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Jul 2015 Primary endpoints been amended.
    • 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov reccord.
    • 12 Jan 2012 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top